Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics has disclosed additional details on the allocation of the HK$392.7 million net proceeds from its global offering, as per Hong Kong Stock Exchange rules. The funds are earmarked for various R&D activities, local production, and technology development, with a significant portion still unutilized as of the end of 2023. These investments aim to support the company’s core and key products development, with a timeline extending up to 2029 for full utilization.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.